Usui Noriko | Jikei Univ. Hospital Tokyo Jpn
スポンサーリンク
概要
関連著者
-
Usubuchi Noriko
Hematology And Oncology Division National Cancer Center Hospital East
-
Usubuchi Noriko
国立がんセンター中央病院
-
USUI Noriko
Division of Oncology and Hematology, Department of Internal Medicine, Jikei University School of Med
-
Takayama K
Department Of Hematology And Oncology Nagoya University Graduate School Of Medicine
-
Takahashi Masatomo
聖マリアンナ医科大学 血液・腫瘍内科
-
Morishima Y
Department Of Hematology Kinki University School Of Medicine
-
Tobinai K
Hematology And Stem Cell Transplantation Divisions National Cancer Center Hospital
-
Moriwaki Yuji
長崎大学大学院医歯薬学総合研究科附属原爆後障害医療研究施設 分子治療研究分野
-
Takahashi Masatomo
Division Of Hematology And Oncology Department Of Internal Medicine St. Marianna University School O
-
Kishimoto Yuji
The First Department Of Internal Medicine Kansai Medical University
著作論文
- Elevated serum levels of human matrix metalloproteinase-9 (MMP-9) during the induction of peripheral blood stem cell mobilization by granulocyte colony-stimulating factor (G-CSF)
- Intensifying Daunorubicin in Induction for Patients with Core Binding Factor Leukemia
- Intensified Daunorubicin in Induction Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Postremission Therapy (Double-7 Protocol) for Adult Acute Myeloid Leukemia
- A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL
- Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate (^Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma
- Durable Response but Prolonged Cytopenia after Cladribine Treatment in Relapsed Patients with Indolent non-Hodgkin's Lymphomas : Results of a Japanese Phase II Study
- Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia
- Early cytomegalovirus (CMV) gastrointestinal disease that developed 19 days after bone marrow transplantation, with a high-level of CMV antigenemia, of up to 1120 cells/slide
- Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia : results of a prospective study in Japan
- Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia : final results of Japanese multicenter cooperative study